title: [Results of hematopoietic cell transplantation in the first complete remission in children with acute myeloid leukemia from an intermediate risk group].
abstract: OBJECTIVE
  To analyze the results of allogeneic and autologous hemopoietic cell transplantations (allo- and auto-HCT) in children with acute myeloid leukemia (AML) from an intermediate risk group, most of which were performed using lower-intensity conditioning modes. SUBJECTS AND METHODS. The study enrolled 36 children from an intermediate risk group, who had undergone auto-HCT (n = 22) or allo-HCT (n = 14) in December 1994 to December 2008. The patients' age was 0.7 to 16.6 years (median 12.8 years). Chemotherapeutic conditioning regimens were applied to all the patients. Melphalan was a basic myeloablative agent in 83.3% of cases.
  
  
  RESULTS
  With a median follow-up of 4.6 years (1.1-13.8 years), three-year relapse-free survival (RFS) was 80.4%; overall survival (OS) was 65.6%. Recurrences were documented only in 6 (16.6%) patients from the auto-HCT. Transplantation-associated mortality (TAM) was 13.8% (five patients died). After allo-HCT versus auto-HCT, RFS, OS, and TAM were 100 and 68.7% (p = 0.03), 93.2 and 55.5% (p = 0.02), and 7.1 and 18.2%, respectively. Acute and chronic graft-versus-host reactions developed in 57.1 and 23.1%, respectively.
  
  
  CONCLUSIONS
  Transplantation of allogeneic hemopoietic cells from a compatible related donor in the intermediate risk group children with AML, by using melphalan-based conditioning regimen, demonstrates a high survival rate with the minimum toxicity.
authors.forename: Z M
authors.initials: ZM
authors.lastname: SDyshlevaia
authors.forename: E V
authors.initials: EV
authors.lastname: Skorobogatova
authors.forename: M A
authors.initials: MA
authors.lastname: Maschan
authors.forename: I P
authors.initials: IP
authors.lastname: Shipitsyna
authors.forename: Iu V
authors.initials: IuV
authors.lastname: Skvortsova
authors.forename: P E
authors.initials: PE
authors.lastname: Trakhtman
authors.forename: D N
authors.initials: DN
authors.lastname: Balashov
authors.forename: Iu V
authors.initials: IuV
authors.lastname: Pashko
authors.forename: E E
authors.initials: EE
authors.lastname: Kurnikova
authors.forename: E V
authors.initials: EV
authors.lastname: Suntsova
authors.forename: O V
authors.initials: OV
authors.lastname: Goronkova
authors.forename: G G
authors.initials: GG
authors.lastname: Solopova
authors.forename: D D
authors.initials: DD
authors.lastname: Baĭdil'dina
authors.forename: I I
authors.initials: II
authors.lastname: Kalinina
authors.forename: L A
authors.initials: LA
authors.lastname: Khachatrian
authors.forename: M M
authors.initials: MM
authors.lastname: Shneĭder
authors.forename: A A
authors.initials: AA
authors.lastname: Maschan
mesh_terms: D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D018572:Disease-Free Survival; D005260:Female; D006085:Graft Survival; D006087:Graft vs Host Reaction; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods* / Q000401:mortality; D006801:Humans; D007223:Infant; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000401:mortality / Q000601:surgery*; D008297:Male; D012008:Recurrence; D012074:Remission Induction; D012306:Risk; D019172:Transplantation Conditioning / Q000379:methods*; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous